Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Tangible Net Worth Ratio
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Tangible Net Worth Ratio of 100.0% as of March 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($1.80 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Cadrenal Therapeutics, Inc. Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Cadrenal Therapeutics, Inc. Common Stock Tangible Net Worth Ratio (2023–2025)
This chart shows how Cadrenal Therapeutics, Inc. Common Stock's Tangible Net Worth Ratio has changed across 3 annual periods from 2023 to 2025. As of March 2026, the ratio stands at 100.0%, reflecting net assets of $1.80 Million with intangible assets of $0.00 USD. See Cadrenal Therapeutics, Inc. Common Stock (CVKD) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Cadrenal Therapeutics, Inc. Common Stock (2023–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Cadrenal Therapeutics, Inc. Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Cadrenal Therapeutics, Inc. Common Stock market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | $2.74 Million | $0.00 | $4.33 Million | ▲ +0.0 pp |
| 2024 | 100.0% | $7.44 Million | $0.00 | $10.12 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $7.69 Million | $0.00 | $8.52 Million | — |